You are here

WHO Progress report Hepatitis.png
Go to Website

Progress report on access to hepatitis C treatment. Focus on overcoming barriers in low- and middle-income countries

by
World Healith Organization

Increased access to highly effective direct-acting antivirals (DAAs) for the treatment of infection with the hepatitis C virus (HCV) is revolutionizing the prospect of ending HCV epidemics. Globally, the number of people who initiated DAA-based treatment for HCV rose between 2015 and 2016, from approximately 1 million to 1.5 million.

This report updates the first edition, published in 2016, and reviews the progress countries have made in expanding access to life-saving DAAs. The report reviews the main challenges countries face and describes recent developments in relation to five key factors that determine access to DAA medicines: affordability, quality assurance, regulatory approval, government commitment and financing. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.

  • General public
  • NGOs
  • People who use drugs (PUD)
  • Global
  • Advocacy
  • Affordability
  • Laws and regulations
  • Monitoring and Evaluation
  • Prevention
  • Treatment
  • Universal access
  • Viral hepatitis

Twitter News